Title:Therapeutics and Research Related to Glioblastoma: Advancements and Future Targets
Volume: 21
Issue: 3
Author(s): Vishal Chavda, Vimal Patel, Dhananjay Yadav, Jigar Shah, Snehal Patel*Jun-O Jin*
Affiliation:
- Department of Pharmacology, Nirma University, Ahmadabad, Gujarat, 382481,India
- Department of Medical Biotechnology, Yeungnam University, Gyeongsan, 712-749,Korea
Keywords:
Glioblastoma, immunology, therapeutics, GQDs, cancer, diagnosis.
Abstract: Glioblastoma, the most common primary brain tumor, has been recognized as one of the most lethal and
fatal human tumors. It has a dismal prognosis, and survival after diagnosis is less than 15 months. Surgery and radiotherapy
are the only available treatment options at present. However, numerous approaches have been made to upgrade
in vivo and in vitro models with the primary goal of assessing abnormal molecular pathways that would be
suitable targets for novel therapeutic approaches. Novel drugs, delivery systems, and immunotherapy strategies to
establish new multimodal therapies that target the molecular pathways involved in tumor initiation and progression in
glioblastoma are being studied. The goal of this review was to describe the pathophysiology, neurodegeneration
mechanisms, signaling pathways, and future therapeutic targets associated with glioblastomas. The key features have
been detailed to provide an up-to-date summary of the advancement required in current diagnosis and therapeutics
for glioblastoma. The role of nanoparticulate system graphene quantum dots as suitable therapy for glioblastoma has
also been discussed.
